Search results for " Immunoglobulin Heavy Chain"

showing 3 items of 3 documents

Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA‐DR and DQ allele frequency

2007

OBJECTIVE: To investigate the relationship of the polymorphic enhancer HS1,2 central to the 3' enhancer complex regulatory region (IgH3'EC) of the immunoglobulin heavy chain genes with systemic sclerosis (SSc) disease and compare it with HLA-DR and DQ associations. METHODS: A total of 116 patients with SSc were classified as diffuse (dSSc) or limited (lSSc), and as carriers of antitopoisomerase I (anti-Scl70) or anticentromere (ACA) antibodies. Allele and genotype frequencies were assessed in the population as a whole and in the two major subsets, dSSc and lSSc. The concentration of peripheral blood immunoglobulin levels was also determined and analysed according to the genotypes. RESULTS: …

MaleSettore MED/16 - REUMATOLOGIAsystemic sclerosisclinical evaluationgenotype phenotype correlationHLA DR antigenSclerodermaGene FrequencyGenotypeImmunology and Allergycentromere antibody; HLA DR antigen; immunoglobulin enhancer binding protein; scl 70 antibody; adult; aged; article; clinical evaluation; controlled study; DNA polymorphism; female; gene frequency; genotype phenotype correlation; human; major clinical study; male; priority journal; risk factor; systemic sclerosis; Adult; Aged; Autoantibodies; Enhancer Elements (Genetics); Esophagus; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; HLA-DQ Antigens; HLA-DR Antigens; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Phenotype; Polymorphism Genetic; Scleroderma Systemic; Statistics Nonparametric; Stomacheducation.field_of_studycentromere antibodyStatisticsStomacharticleMiddle AgedExtended Reportimmunoglobulin enhancer binding proteinEnhancer Elements GeneticPhenotypepriority journalrisk factorFemaleImmunoglobulin Heavy ChainsAdultGenotypeImmunologyPopulationBiologyGeneral Biochemistry Genetics and Molecular BiologyStatistics NonparametricEsophagusGeneticRheumatologyHLA-DQ AntigensHLA-DRHumanscontrolled studyEnhancer Elements (Genetics)NonparametricGenetic Predisposition to DiseasehumanPolymorphismAlleleeducationEnhancerAllele frequencyAgedAutoantibodiesscl 70 antibodyPolymorphism GeneticScleroderma SystemicSystemicHLA-DR Antigensmajor clinical studyGenotype frequencySettore BIO/18 - GeneticaDNA polymorphismImmunologyImmunoglobulin heavy chain
researchProduct

Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.

2012

We performed an immunogenetic analysis of 345 IGHV-IGHD-IGHJ rearrangements from 337 cases with primary splenic small B-cell lymphomas of marginal-zone origin. Three immunoglobulin (IG) heavy variable (IGHV) genes accounted for 45.8% of the cases (IGHV1-2, 24.9%; IGHV4-34, 12.8%; IGHV3-23, 8.1%). Particularly for the IGHV1-2 gene, strong biases were evident regarding utilization of different alleles, with 79/86 rearrangements (92%) using allele *04. Among cases more stringently classified as splenic marginal-zone lymphoma (SMZL) thanks to the availability of splenic histopathological specimens, the frequency of IGHV1-2*04 peaked at 31%. The IGHV1-2*04 rearrangements carried significantly lo…

Immunoglobulin geneModels MolecularCancer ResearchGenes Immunoglobulin Heavy ChainGene Rearrangement B-Lymphocyte Heavy ChainImmunoglobulin Variable RegionSomatic hypermutationSplenic NeoplasmBiologyCohort StudiesantigenmedicineHumansSplenic marginal zone lymphomaAlleleGeneticsSplenic Neoplasmssplenic marginal-zone lymphomaHematologyGene rearrangementLymphoma B-Cell Marginal Zonemedicine.diseasePrognosisComplementarity Determining Regionssomatic hypermutationimmunoglobulin geneOncologyMutationIGHDsplenic marginal-zone lymphoma; immunoglobulin gene; somatic hypermutation; CDR3; antigenCDR3IGHV@Leukemia
researchProduct

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

2010

Abstract The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive …

glycoproteinMaleTime FactorsZAP-70Chronic lymphocytic leukemiavascular endothelial growth factor aBiochemistryGastroenterologyimmunoglobulin heavy chainsAdult Aged Aged; 80 and over Angiopoietin-2; analysis/blood Blood Chemical Analysis Female Humans Leukemia; Lymphocytic; Chronic; B-Cell; blood/diagnosis/mortality/therapy Male Middle Aged Neoadjuvant Therapy Prognosis Survival Analysis Time Factors Tumor Markers; Biological; bloodBlood plasma80 and overChronicTumor MarkersAged 80 and overLeukemiaHematologyHazard ratioprotein kinaseHematologyanalysis/bloodMiddle Agedchronic b-cell leukemiasPrognosisLymphocyticNeoadjuvant TherapyLeukemiaCohortFemaleAdultmedicine.medical_specialtyImmunologyangiopoietins chronic b-cell leukemias chronic lymphocytic leukemia plasma vascular endothelial growth factor a cd38 enzyme-linked immunosorbent assay glycoprotein immunoglobulin heavy chains protein kinaseNOcd38Angiopoietin-2bloodInternal medicinemedicineBiomarkers Tumorchronic lymphocytic leukemia angiopoietin-2.Humansbeta(2)-microglobulinplasmaSurvival analysisblood/diagnosis/mortality/therapyAgedbusiness.industryB-CellCell BiologyBiologicalmedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisConfidence intervalImmunologychronic lymphocytic leukemiaangiopoietin-2enzyme-linked immunosorbent assaybusinessCLL; angiopoietin-2; beta(2)-microglobulin; ZAP-70; CD38Settore MED/15 - Malattie del SangueangiopoietinsBlood Chemical AnalysisCLLCD38Blood Chemical Analysis; Angiopoietin-2; Humans; Neoadjuvant Therapy; Prognosis; Aged; Aged 80 and over; Leukemia Lymphocytic Chronic B-Cell; Adult; Middle Aged; Tumor Markers Biological; Time Factors; Female; Male; Survival Analysis
researchProduct